Tumour control by whole brain irradiation of anti-VEGF-treated mice bearing intracerebral glioma Journal Article


Authors: Verhoeff, J. J. C.; Stalpers, L. J. A.; Claes, A.; Hovinga, K. E.; Musters, G. D.; Peter Vandertop, W.; Richel, D. J.; Leenders, W. P. J.; van Furth, W. R.
Article Title: Tumour control by whole brain irradiation of anti-VEGF-treated mice bearing intracerebral glioma
Abstract: Aim of the study: Tumour angiogenesis and invasion are key features of glioblastoma multiforme (GBM). Angiogenesis inhibitors increase progression-free survival (PFS) of recurrent GBM patients. VEGF inhibition controls the bulk tumour growth by inhibition of angiogenesis, but does not inhibit the invasive tumour component. We investigated if invasive tumour growth can be controlled by combining anti-VEGF treatment with irradiation of tumour plus surrounding brain in an orthotopic murine model for GBM. Methods and materials: GBM cell line U251-NG2 was inoculated through a guide screw in the right frontal lobe of 53 athymic nude mice. Pegaptanib (a slow-releasing aptamer against VEGF) was injected in the tumour bed either or not followed by irradiation treatment with implanted I-125 seeds. Pegaptanib and/or irradiation were compared with sham-treated controls, resulting in four groups of 10-15 mice each. After 6 weeks of treatment, histological analysis was performed on all brains. Results: VEGF inhibition by locally deposited pegaptanib decreased tumour blood vessel density, and increased tumour hypoxia. Pegaptanib treatment still allowed the formation of tumour satellites. Irradiation decreased tumour size and suppressed formation of satellites. Combined pegaptanib plus irradiation further increased PFS. Tumour size directly correlated with PFS. Concluding statement: The anti-tumour effects of local VEGF inhibition are partially circumvented by the formation of invasive tumour satellites. Additional irradiation is effective in slowing down proliferation of these invasive tumour components. © 2009 Elsevier Ltd. All rights reserved.
Keywords: cancer survival; controlled study; treatment outcome; disease-free survival; vascular endothelial growth factor a; human cell; histopathology; multimodality cancer therapy; nonhuman; treatment duration; combined modality therapy; brain radiation; glioma; brain neoplasms; mouse; animals; mice; animal tissue; progression free survival; tumor volume; animal experiment; animal model; antineoplastic activity; drug effect; neovascularization, pathologic; cancer model; cancer inhibition; iodine 125; nude mouse; mice, nude; glioblastoma; tumor cell line; irradiation; neoplasm invasiveness; clinical effectiveness; neoplasm transplantation; cancer control; disease models, animal; angiogenesis inhibitors; tumor vascularization; hypoxemia; anti-angiogenesis; radioisotope therapy; sham procedure; aptamers, nucleotide; orthotopic; pegaptanib
Journal Title: European Journal of Cancer
Volume: 45
Issue: 17
ISSN: 0959-8049
Publisher: Elsevier Inc.  
Date Published: 2009-11-01
Start Page: 3074
End Page: 3080
Language: English
DOI: 10.1016/j.ejca.2009.08.004
PUBMED: 19734041
PROVIDER: scopus
DOI/URL:
Notes: --- - "Cited By (since 1996): 1" - "Export Date: 30 November 2010" - "CODEN: EJCAE" - "Source: Scopus"
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors